Todos

Todos Medical Announces Insolvency Proceedings in Israel

Retrieved on: 
Friday, December 22, 2023
Long, Todos, Annual report, Form, TEL, Form S-1, Court, Medical food, Hamas, Element, NLC, COVID, OTCQB, Trustee, ALS, Hearing

Due to unforeseen setbacks and adverse market conditions during the listing process, the Company was unable to effect the NYSE American and related public offering.

Key Points: 
  • Due to unforeseen setbacks and adverse market conditions during the listing process, the Company was unable to effect the NYSE American and related public offering.
  • The Company made the first payment, of $24,000, to Mr. ZIgdon in January 2023.
  • In December 2023, a trustee was appointed by the Court of Insolvency to oversee the liquidation of Todos Medical Ltd. in Israel.
  • Regardless of the outcome of the matters before the Court of Insolvency in Israel, Todos Medical and NLC Pharma are committed to ensuring that all customers who have placed orders for Tollovid via www.mytollovid.com will receive their orders.

Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp

Retrieved on: 
Thursday, September 22, 2022
Adult, Duke Diet and Fitness Center, Virus, Legislation, Cliburn, Pressure, Redbox, Lymphocyte, USD, Patient, MERS, U.S. Securities and Exchange Commission, Technology, Lowe's Market, TMB-2, Todos, Research, Candy, Monocyte, PCR, Synthase, COVID-19, Knowledge, CBD, Company, COVID, TBIA, Amazon, CAGR, Apoptosis, University, TEL, Severe acute respiratory syndrome coronavirus 2, OTCQB, Travel, CEO, Method, GLOBE, IRB, Airport, Immune system, Cancer, Neurodegeneration, Plasma, Alzheimer's disease, Southwestern United States, Cancer immunotherapy, Brain, Intelligence, Solution, Biotechnology, Cell cycle, Overalls, Awareness, Neuron, Retail, Online shopping, Pharmaceutical industry, Medical imaging, Pharma

The new Tollovid and CBD products for the AI Retail machines will be manufactured in different adult and pediatric formulations in the Todos newly leased Cleburn, Texas-based facility.

Key Points: 
  • The new Tollovid and CBD products for the AI Retail machines will be manufactured in different adult and pediatric formulations in the Todos newly leased Cleburn, Texas-based facility.
  • Todos anticipates $11.5 million in revenue in the fourth quarter of 2022 from this contract as Nerd Hemp commences its nationwide rollout.
  • Nerd Hemp was founded in 2019 with a focus on launching CBD products to the marketplace through automated retail (AI Retail) machines.
  • Nerd Hemp intends to launch its CBD AI Retail machines in retail locations nationwide through its strategic distribution channels.

Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma

Retrieved on: 
Monday, September 12, 2022
Virus, Legislation, Pressure, Lymphocyte, Patient, MERS, U.S. Securities and Exchange Commission, Technology, TMB-2, Todos, Research, Monocyte, PCR, Synthase, Death, EUA, COVID-19, Knowledge, Company, NLC, IP, COVID, TBIA, Amazon, Patent, Apoptosis, Severe acute respiratory syndrome coronavirus 2, OTCQB, Emergency Use Authorization, Aerospace, CEO, Method, GLOBE, IRB, Fatigue, Immune system, Cancer, Neurodegeneration, Plasma, Alzheimer's disease, CCR5, UK Coronavirus Cancer Monitoring Project, Brain, Harvard University, Solution, Biotechnology, Cell cycle, Neuron, Pharmaceutical industry, Online shopping, Medical imaging, Pharma

Additionally, this empowers investors with a vehicle that can capture the essence of a pure play opportunity in 3CL protease inhibition.

Key Points: 
  • Additionally, this empowers investors with a vehicle that can capture the essence of a pure play opportunity in 3CL protease inhibition.
  • The 3CL protease market is dominated by Pfizers COVID-19 drug which is expected to do $22 billion this year.
  • All-natural 3CL protease inhibitors like Tollovid offer consumers an all-natural versus chemical option and the ability to have 3CL protease inhibition sitting in their medicine cabinet today.
  • Assigning the IP to 3CL Pharma is a crucial step to enable building the appropriate corporate infrastructure to raise funds for the 3CL.

Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign

Retrieved on: 
Friday, September 2, 2022
Cancer prevention, Cell cycle, CEO, Technology, OTCQB, TBIA, Monocyte, Gross domestic product, Neuron, Neurodegeneration, Research, Legislation, Awareness, Brain, Solution, Synthase, Pressure, TMB-2, Todos, U.S. Securities and Exchange Commission, Method, Alzheimer's disease, PCR, Plasma, Company, Immune system, Biotechnology, Lymphocyte, Cancer, Association, Knowledge, Federal Reserve, Amazon, COVID, Apoptosis, Federal, Pharmaceutical industry, Medical imaging, Long COVID, Pharma

New York, NY, and Tel Aviv, ISRAEL, Sept. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into a brand ambassador agreement with Kingcarlx, an American influencer with over 7.4 million followers across all platforms (5.8 million on TikTok, 1 million on Instagram and 600,000 on YouTube), for the Company’s majority-owned 3CL Pharma Ltd. subsidiary’s Tollovid™ 3CL protease inhibitor immune support dietary supplement brand. Together with Kingcarlx, the Company is launching the #TolloUp marketing campaign. Kingcarlx will be focused on promoting the lifestyle aspects of the Tollovid brand focused on encouraging followers to use the supplement on a daily basis for added protection in the face of a pandemic world.

Key Points: 
  • We are beginning to make progress in gaining awareness in the marketplace for our Tollovid supplement and as well as with the investment community, said Gerald Commissiong, President & CEO of Todos Medical.
  • Tollovid is an absolutely timely brand for todays challenges.
  • I believe that a Kingcarlx #TolloUp marketing campaign alongside B2i Digital investor relations platform are important steps forward towards achieving our objectives.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics

Retrieved on: 
Friday, August 5, 2022
U.S. Securities and Exchange Commission, Medicare, GLOBE, Brain, Research, Knowledge, Method, Patient, Monocyte, TBIA, Immune system, Diagnosis, Neuron, Technology, Cell cycle, Lymphocyte, Partnership, Biotechnology, Neurodegeneration, IRB, Pressure, OTCQB, Physician, Apoptosis, COVID, GA, Cancer, Synthase, MERS, COVID-19, Virus, Solution, Severe acute respiratory syndrome coronavirus 2, PCR, Legislation, Population, Lists of diseases, Plasma, Company, TMB-2, Alzheimer's disease, Todos, Cancer immunotherapy, Long COVID, Quest Diagnostics, Vaccine, Pharmaceutical industry, Medical imaging, Pharma

New York, NY, and Tel Aviv, ISRAEL, Aug. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the first commercial patient samples have been received for its Long COVID Panel biomarker partnership between its CLIA/CAP certified lab Provista Diagnostics and Amerimmune Diagnostics, a CLIA/CAP certified laboratory with expertise in immune diagnostics and a leader in the field of clinical immunology and immune assessment of acute and long-COVID. The patient samples received were requisitioned by Long COVID Clinic RTHM (Real Time Health Monitoring), the partnership’s first Long COVID Clinic client, collected at a Quest Diagnostics service center in the United States and shipped to Amerimmune’s lab in McLean, Virginia for processing. The cPass neutralizing antibody and total antibody portion of the panel is being subcontracted to Provista in Atlanta, GA and the data sent back to Amerimmune to include in their report back to the RTHM physician. The various biomarker tests included in the Long COVID Panel are covered by commercial insurance and Medicare.

Key Points: 
  • The various biomarker tests included in the Long COVID Panel are covered by commercial insurance and Medicare.
  • The objective is for Long COVID Panel data to be included in Todos ongoing Tollovid case study series going forward to corroborate perceived patient benefit.
  • Founded in 2010, Amerimmune Diagnostics focuses on immunological testing as a solution to the unmet need and timely diagnosis of immune disorders.
  • Preliminary data from an ongoing IRB-waiver study of customers who used the products to assist with their COVID and Long COVID was recently announced.

Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs

Retrieved on: 
Tuesday, March 8, 2022
Government, U.S. Securities and Exchange Commission, Knowledge, Neurodegeneration, Plasma, Monocyte, Biotechnology Innovation Organization, COVID-19, Alzheimer's disease, BIO, ICU, Pressure, PCR, OTC, Neuron, Long, Lymphocyte, Adult, Pharma, Solution, Method, Disability, Company, Cancer, CEO, OTCQB, Brain, Legislation, International relations, Long COVID, Risk, Apoptosis, COVID, Hospital, Policy, VP, Synthase, Roswell Park Comprehensive Cancer Center, Child, Technology, Coronavirus, Immune system, TMB-2, Tufts University, Infection, Government Affairs Institute, Patient, Cell cycle, Research, Biotechnology, Intubation, Tollo, TBIA, GLOBE, Pharmaceutical industry, Todos

New York, NY, and Tel Aviv, ISRAEL, March 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has appointed Greg Meiselbach as Vice President of Government Affairs.

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, March 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has appointed Greg Meiselbach as Vice President of Government Affairs.
  • Mr. Meiselbach brings over 10 years of government and business development experience in the biotechnology industry to Todos.
  • We see significant potential to bring Tollovir to governments as a key solution for hospital overutilization which is currently the biggest risk to national healthcare systems, said Greg Meiselbach, VP of Government Affairs at Todos.
  • Prior to REEF, Mr. Meiselbach was Director for International Affairs at the Biotechnology Innovation Organization (BIO) for five years.

Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients

Retrieved on: 
Monday, January 24, 2022
U.S. Securities and Exchange Commission, PCR, Patient, Research, Technology, UK Coronavirus Cancer Monitoring Project, MERS, Legislation, Neurodegeneration, Biotechnology, Apoptosis, OTCQB, Cell cycle, COVID-19, Severe acute respiratory syndrome coronavirus 2, Joint venture, Science, Knowledge, Synthase, TBIA, Plasma, GLOBE, Solution, Lymphocyte, Cancer, NLC, Acquisition, Infection, Monocyte, Company, Method, Neuron, TMB-2, Immune system, Pressure, International joint venture, Todos, Data analysis, Brain, Alzheimer's disease, COVID, Pharmaceutical industry, Medical imaging

via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease theragnostic joint venture partner NLC Pharma Ltd., today announced a data lock for the interim data analysis for the Company’s Tollovir™ Phase 2 Clinical Trial for the treatment of hospitalized (severe/critical) COVID-19 patients. The Company will release the results on Thursday, January 27th, 2022.

Key Points: 
  • We are very excited to see the first controlled clinical trial data for Tollovir, said Dr. Dorit Arad, Founder & Chief Scientific Officer of NLC Pharma, Todos Medicals 3CL protease biology theragnostics joint venture partner.
  • Tollovir is currently in a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19.
  • Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19.
  • The Companys proprietary therapeutic candidate Tollovir is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to initiate Phase 2/3 clinical trials for both hospitalized and non-hospitalized patients in Israel.

Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies

Retrieved on: 
Tuesday, January 18, 2022
U.S. Securities and Exchange Commission, PCR, Patient, Research, Technology, Cancer prevention, Legislation, Neurodegeneration, Biotechnology, Apoptosis, OTCQB, Newsmax, Cell cycle, COVID-19, Black News Channel, Population, Knowledge, Synthase, Fox Business, EUA, TBIA, CEO, Plasma, Disease, Solution, GLOBE, Lymphocyte, Cancer, NLC, Acquisition, Reading, Monocyte, Company, Method, US Foods, Neuron, International joint venture, Risk, TMB-2, Immune system, Pressure, Infection, Todos, FDA, Brain, Alzheimer's disease, Long COVID, COVID, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, Jan. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today released videos of recent interviews with Fox Business, Black New Channel and NewsMax.

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Jan. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today released videos of recent interviews with Fox Business, Black New Channel and NewsMax.
  • Until this happens, it will be very difficult to return to a normal way of life.
  • Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic.
  • Todos is also distributing certain (COVID-19) testing materials and supplies to CLIA-certified labs in the United States.

Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022

Retrieved on: 
Wednesday, January 12, 2022
U.S. Securities and Exchange Commission, PCR, Patient, Research, Technology, Cancer prevention, Legislation, Neurodegeneration, Biotechnology, Apoptosis, OTCQB, Cell cycle, COVID-19, Knowledge, Synthase, TBIA, Plasma, Solution, GLOBE, Lymphocyte, Cancer, NLC, Acquisition, Monocyte, Company, Method, Neuron, International joint venture, Immune system, TMB-2, Pressure, Todos, Brain, Alzheimer's disease, Pharmaceutical industry, Medical imaging

The Company will provide further details regarding the conference call during the week ending January 17, 2022 when it announces the data lock for the trial.

Key Points: 
  • The Company will provide further details regarding the conference call during the week ending January 17, 2022 when it announces the data lock for the trial.
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic.
  • The Companys proprietary therapeutic candidate Tollovir is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to initiate Phase 2/3 clinical trials for both hospitalized and non-hospitalized patients in Israel.

Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022

Retrieved on: 
Monday, January 10, 2022
U.S. Securities and Exchange Commission, PCR, Patient, Research, Technology, Roswell Park Comprehensive Cancer Center, Legislation, Neurodegeneration, Biotechnology, Apoptosis, OTCQB, Cell cycle, COVID-19, Corner, Joint venture, Knowledge, Synthase, TBIA, Plasma, GLOBE, Solution, Lymphocyte, Cancer, The Claman Countdown, NLC, Acquisition, Monocyte, Company, Method, Blog, Neuron, Immune system, TMB-2, Pressure, International joint venture, Todos, Brain, Everything That Happens Will Happen Today, Alzheimer's disease, COVID, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, Jan. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its President & CEO Gerald Commissiong will appear on Fox Business’ The Claman Countdown on Tuesday, January 11 during the 3pm Eastern Time hour show to discuss COVID testing in the United States and how it relates to the pending availability of oral antiviral treatments such as the Company’s Tollovir™ 3CL protease inhibitor oral antiviral treatment currently preparing to read out on Phase 2 clinical data in hospitalized patients. Mr. Commissiong is also presenting at the Biotech Showcase 2022 to be held virtually from January 10-12th, 2022. Concurrent with this announcement, Mr. Commissiong released a blog entitled “COVID Testing: What Needs to Happen Now to Turn the Corner in 2022” that discusses key points needed to improve the United States COVID testing infrastructure. The blog posting is available online at https://todosmedical.com/blog/covid-testing-what-needs-to-happen-now-to-....

Key Points: 
  • Mr. Commissiong is also presenting at the Biotech Showcase 2022 to be held virtually from January 10-12th, 2022.
  • Please follow the Companys Twitter account for any updates to the time: https://twitter.com/todosmedical
    Registered attendees to Biotech Showcase can access Todos Medicals pre-recorded company presentation prior to the event.
  • Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic.
  • Todos is also distributing certain (COVID-19) testing materials and supplies to CLIA-certified labs in the United States.